Outcomes of Patients After Allo-HSCT With Decitabine and NAC

Launched by THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY · Jun 22, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how effective a new treatment plan is for patients who have undergone a specific type of stem cell transplant called allo-HSCT. The study will focus on how well patients recover after the transplant, whether they experience complications like graft-versus-host disease (GVHD), or if their cancer comes back (relapse). The treatment involves using a medication called decitabine along with another treatment known as NAC.

To be part of this trial, patients need to be between the ages of 10 and 70 and have been diagnosed with a type of blood cancer. They should also be in complete remission after their last chemotherapy session and be open to receiving the stem cell transplant from a matched donor. However, patients with active infections or severe organ problems, or those who are allergic to the study medications, cannot participate. While the trial is not yet recruiting participants, those who join will be closely monitored for their recovery and any side effects from the treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed as hematopoietic malignancy;
• • 2. Achieved complete remission since the last chemotherapy;
• • 3. Age 10-70 years；
• • 4. Be willing to receive allo-HSCT, with HLA matched related or HLA matched unrelated, or HLA mismatched related donor.
• Exclusion Criteria:
• • 1. Active infections, severe organ damage (cardiac, renal and/or hepatic dysfunction greater than grade 2 according to the Common Terminology Criteria for Adverse Events V5.0), or any other conditions that make patients ineligible for allo-HSCT;
• • 2. Allergic to acetylcysteine or decitabine.